Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FOB Savings Reduced To $6.4 Bil. In Revised Budget Outlook; Total Drug Savings, $100 Bil.

This article was originally published in The Pink Sheet Daily

Executive Summary

The administration's expectations for savings from follow-on biologics that can be applied to health care reform are clarified by the mid-year budget review and outlook released by OMB Aug. 25.

You may also be interested in...

Rx Contribution To Health Reform May Be $100 Bil. After All, Obama Suggests

What's another $20 billion among friends? Biopharma executives had to cringe when, during his July 22 press conference on health reform, President Obama discussed the industry's pledge to deliver $80 billion in savings to help fund the effort. Not only was there a rough edge to his description of the agreement, the President seemingly upped the amount industry may end up having to put on the table by 25 percent

Obama Pushing For “Better Prices” For Part D Drugs

White House finds additional $313 billion in savings – $75 billion from drugs – to pay for expanded health care reform.

More Rebates For More Coverage: Budget Seeks Medicaid Rx Rebate Of 22%

An increase in the Medicaid rebate amount to 22.1 percent and changes to how Medicaid rebates are collected account for almost $20 billion of the nearly $634 billion "health reform reserve fund" proposed in the White House's outline of the fiscal 2010 budget


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts